AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14616153 — intervention group
Group type: COMPARATOR
Intervention: Control group (erosive oesophagitis)
Number of subjects: 26
Study 16825934 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day rabeprazole, levofloxacin, tinidazole (RLT)
Number of subjects: 169
Study 16825934 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day rabeprazole, levofloxacin, tinidazole (RLT)
Number of subjects: 169
Study 16825934 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 169
Study 10580457 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice per day
Number of subjects: 1149
Study 10580457 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice per day
Number of subjects: 1149
Study 10580457 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice per day
Number of subjects: 1149
Study 10580457 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice per day
Number of subjects: 1149
Study 10580457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1149
Study 8967597 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 22
Study 8967597 — intervention group
Group type: COMPARATOR
Intervention: No heat and moisture exchanger (Control)
Number of subjects: 22
Study 1848966 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic sympathetic ganglion blocks (LASB)
Number of subjects: 20
Study 1848966 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine blocks (PhB)
Number of subjects: 20
Study 1848966 — intervention group
Group type: COMPARATOR
Intervention: Both LASB and PhB
Number of subjects: 20
Study 6807693 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate, high fibre diet (HC)
Number of subjects: 7
Study 6807693 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate diet (LC)
Number of subjects: 7
Study 30564856 — intervention group
Group type: EXPERIMENTAL
Intervention: SWI
Number of subjects: 37
Study 30564856 — intervention group
Group type: EXPERIMENTAL
Intervention: T1w/SWI
Number of subjects: 37
Study 30564856 — intervention group
Group type: COMPARATOR
Intervention: T1w
Number of subjects: 37
Study 30564856 — intervention group
Group type: COMPARATOR
Intervention: CT (reference standard)
Number of subjects: 37
Study 26661592 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel, capecitabine, and cisplatin (DXP)
Number of subjects: 46
Study 27050431 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (5 to 20 mg/day; n = 20)
Number of subjects: 40
Study 27050431 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study 25234932 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care group (faxed medication care plan and follow-up call)
Number of subjects: 945
Study 25234932 — intervention group
Group type: COMPARATOR
Intervention: Minimal care group (admission history, medication reconciliation, patient education, discharge medication list, and medication recommendations)
Number of subjects: 945
Study 25234932 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 945
Study 25234932 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 945
Study 21659629 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIO‐469 (150, 210, or 300 mg preoperative; 210 mg + 90 mg postoperative)
Number of subjects: 263
Study 21659629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 263
Study 21659629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 19528368 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 administration
Number of subjects: 8
Study 19528368 — intervention group
Group type: COMPARATOR
Intervention: Insulin administration
Number of subjects: 8
Study 17330056 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training programme (12-week treadmill exercise programme, lactate 2.0 mmol/l)
Number of subjects: 52
Study 15271050 — intervention group
Group type: EXPERIMENTAL
Intervention: Free text CAL tutorial
Number of subjects: 0
Study 15271050 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic CAL tutorial
Number of subjects: 0
Study 15271050 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-CAL users)
Number of subjects: 0
Study 15271050 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based CAL tutorial
Number of subjects: 0
Study 11442289 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-breath alkane uptake
Number of subjects: 0
Study 9516220 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of troglitazone
Number of subjects: 350
Study 9516220 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of troglitazone
Number of subjects: 350
Study 9516220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 7977117 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol 0.5 g, twice daily
Number of subjects: 274
Study 7977117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 31238920 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Patient (SP) module
Number of subjects: 113
Study 31238920 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Role-Play (RP) module
Number of subjects: 113
Study 31238920 — intervention group
Group type: COMPARATOR
Intervention: Control (Baseline)
Number of subjects: 113
Study 28387007 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational feedback based on Project CHOICES
Number of subjects: 354
Study 28387007 — intervention group
Group type: COMPARATOR
Intervention: Information only
Number of subjects: 354
Study 25655470 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-453859 100 mg once a day
Number of subjects: 0
Study 25655470 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-453859 800 mg once a day
Number of subjects: 0
Study 25655470 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-453859 (dose unspecified)
Number of subjects: 0
Study 23500234 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 399
Study 23500234 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 399
Study 21223566 — intervention group
Group type: EXPERIMENTAL
Intervention: k‐t BLAST factor of two
Number of subjects: 0
Study 21223566 — intervention group
Group type: EXPERIMENTAL
Intervention: k‐t BLAST factor greater than two
Number of subjects: 0
Study 21223566 — intervention group
Group type: EXPERIMENTAL
Intervention: k‐t BLAST
Number of subjects: 0
Study 18262443 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential (IF) stimulation followed by patterned muscle stimulation for 15 min and 20 min respectively, treated for 8 weeks
Number of subjects: 116
Study 18262443 — intervention group
Group type: COMPARATOR
Intervention: Low-current transcutaneous electrical nerve stimulation (TENS) for 35 min, treated for 8 weeks
Number of subjects: 116
Study 16873389 — intervention group
Group type: EXPERIMENTAL
Intervention: ANH
Number of subjects: 56
Study 12554153 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide analysis using HPLC method
Number of subjects: 0
Study 12554153 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal standard (phenytoin)
Number of subjects: 0
Study 10688505 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced schedule (34, 38, 41 weeks) with home blood pressure monitoring
Number of subjects: 80
Study 10688505 — intervention group
Group type: COMPARATOR
Intervention: Standard nine subsequent visit schedule (30, 32, 34, 36, 37, 38, 39, 40, 41 weeks)
Number of subjects: 80
Study 10688505 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced schedule with home blood pressure monitoring
Number of subjects: 80
Study 9110098 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (4.5 micrograms/kg, IM)
Number of subjects: 48
Study 9110098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8409311 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradicating treatment (colloidal bismuth subcitrate plus metronidazole)
Number of subjects: 53
Study 8409311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 53
Study 8409311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 3752982 — intervention group
Group type: EXPERIMENTAL
Intervention: Novobiocin (500 mg) administered orally, twice a day for 27 doses
Number of subjects: 10
Study 3752982 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (300 mg) administered orally, twice a day for 27 doses
Number of subjects: 10
Study 3752982 — intervention group
Group type: EXPERIMENTAL
Intervention: Novobiocin and rifampin administered in combination
Number of subjects: 10
Study 30113466 — intervention group
Group type: EXPERIMENTAL
Intervention: Assist‐as‐needed robot‐assisted gait training for the unaffected limb and fully‐assisted robot‐assisted training for the affected limb (Group 1)
Number of subjects: 24
Study 30113466 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot‐assisted gait training using the opposite protocol (Group 2)
Number of subjects: 24
Study 26719212 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess gestational weight gain
Number of subjects: 49
Study 26719212 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate gestational weight gain
Number of subjects: 49
Study 26719212 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate gestational weight gain
Number of subjects: 49
Study 24996128 — intervention group
Group type: EXPERIMENTAL
Intervention: nab‐paclitaxel (500 mg/100 ml) administered in 6 weekly intravesical instillations
Number of subjects: 28
Study 22983558 — intervention group
Group type: EXPERIMENTAL
Intervention: eCare (Internet-delivered care management and patient self-management program)
Number of subjects: 103
Study 22983558 — intervention group
Group type: EXPERIMENTAL
Intervention: eCare
Number of subjects: 103
Study 22983558 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 103
Study 20801608 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser therapy (EVLT) (980 nm)
Number of subjects: 204
Study 20801608 — intervention group
Group type: COMPARATOR
Intervention: High ligation and stripping (HL/S)
Number of subjects: 204
Study 20801608 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser therapy (EVLT)
Number of subjects: 204
Study 20801608 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser therapy (EVLT) and High ligation and stripping (HL/S)
Number of subjects: 204
Study 19247898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular sodium nitroprusside (SNP)
Number of subjects: 20
Study 19247898 — intervention group
Group type: COMPARATOR
Intervention: Control group (major systemic illness or did not consent)
Number of subjects: 20
Study 15831835 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted subthreshold cortical stimulation guided by fMRI
Number of subjects: 12
Study 15831835 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI (fMRI) guidance
Number of subjects: 12
Study 12929898 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH materials in intervention schools
Number of subjects: 76
Study 12929898 — intervention group
Group type: COMPARATOR
Intervention: Control schools received training and materials
Number of subjects: 76
Study 10480957 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg of rhMnSOD
Number of subjects: 72
Study 10480957 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 72
Study 8735679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal quinine gluconate (12.8 mg kg‐1)
Number of subjects: 21
Study 8735679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Quinimax (8 mg kg‐1)
Number of subjects: 21
Study 8735679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Quinimax (8 mg kg‐1, 4 h infusion)
Number of subjects: 21
Study 1685090 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol 0.5 mg
Number of subjects: 12
Study 1685090 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol 1.0 mg
Number of subjects: 12
Study 1685090 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol 2.0 mg
Number of subjects: 12
Study 1685090 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 7128662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclothiazide (2.5 mg daily)
Number of subjects: 13
Study 7128662 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorthiazide-amiloride combination (50 + 5 mg daily)
Number of subjects: 13
Study 29754654 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT), n = 527
Number of subjects: 2052
Study 29754654 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone, n = 1525
Number of subjects: 2052
Study 27275859 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous high-dose omeprazole infusion for 72 hours
Number of subjects: 305
Study 27275859 — intervention group
Group type: COMPARATOR
Intervention: Scheduled second-look endoscopy with intravenous omeprazole bolus every 12 hours for 72 hours
Number of subjects: 305
Study 24124121 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation (SA) intervention using a 32-item values affirmation questionnaire
Number of subjects: 0
Study 24124121 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22336262 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (extra daily dose inhaled 8 hours after previous dose)
Number of subjects: 56
Study 22336262 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol t.i.d.
Number of subjects: 56
Study 22336262 — intervention group
Group type: COMPARATOR
Intervention: Formoterol b.i.d. + placebo
Number of subjects: 56
Study 20059698 — intervention group
Group type: EXPERIMENTAL
Intervention: Acotiamide 100 mg t.i.d.
Number of subjects: 0
Study 20059698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18537181 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha‐tocopherol 600 IU/day plus ascorbic acid 500 mg/day
Number of subjects: 53
Study 18537181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 15918811 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy challenge (EC)
Number of subjects: 92
Study 15918811 — intervention group
Group type: COMPARATOR
Intervention: Sham alcohol experiment (control)
Number of subjects: 92
Study 14633947 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal gas infusion (12 ml/min for one hour)
Number of subjects: 14
Study 14633947 — intervention group
Group type: COMPARATOR
Intervention: Rectal gas infusion (12 ml/min for one hour)
Number of subjects: 14
Study 14633947 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal gas infusion
Number of subjects: 14
Study 14633947 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic gas loads
Number of subjects: 14
Study 14633947 — intervention group
Group type: EXPERIMENTAL
Intervention: Both jejunal and rectal gas infusion
Number of subjects: 14
Study 11052956 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exercise (2 hours at 64 +/- 1% of maximal oxygen uptake)
Number of subjects: 8
Study 11052956 — intervention group
Group type: COMPARATOR
Intervention: Control (no prior exercise)
Number of subjects: 8
Study 11052956 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exercise
Number of subjects: 8
Study 8797120 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual semiquantitative (SQ) assessment by an experienced radiologist
Number of subjects: 503
Study 8797120 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual flagging by research assistants
Number of subjects: 503
Study 8797120 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative morphometry (QM) >= 3 SD
Number of subjects: 503
Study 8797120 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative morphometry (QM) 15
Number of subjects: 503
Study 8797120 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination assessment of SQ and QM
Number of subjects: 503
Study 1639992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (individualized doses)
Number of subjects: 11
Study 1639992 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 11
Study 6702238 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% fat solution containing 50 g/l medium chain triglycerides (MCT) and 50 g/l long chain triglycerides (LCT)
Number of subjects: 18
Study 6702238 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 18
Study 30415310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg/day for 3 months)
Number of subjects: 30
Study 30415310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (1 µM)
Number of subjects: 30
Study 30415310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 30
Study 30415310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27317188 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone (HYD) 20, 40, 60, 80, or 120 mg once daily
Number of subjects: 26
Study 27317188 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone (HYD)
Number of subjects: 26
Study 27653735 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive plus restriction (30% financial incentive for fruits and vegetables and restriction of purchase of sugar sweetened beverages, sweet baked goods, or candy)
Number of subjects: 279
Study 27653735 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive plus restriction
Number of subjects: 279
Study 27653735 — intervention group
Group type: COMPARATOR
Intervention: Control (no incentive or restrictions)
Number of subjects: 279
Study 24837512 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR SII (aerosol)
Number of subjects: 260
Study 24837512 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR II (aerosol)
Number of subjects: 260
Study 24837512 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR SII (injection)
Number of subjects: 260
Study 24837512 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR II (injection)
Number of subjects: 260
Study 22484516 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensation seekers
Number of subjects: 40
Study 22484516 — intervention group
Group type: COMPARATOR
Intervention: Low sensation seekers
Number of subjects: 40
Study 19456235 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Lactobacillus colonization
Number of subjects: 151
Study 19456235 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast identified on wet preparation of vaginal secretions
Number of subjects: 151
Study 19456235 — intervention group
Group type: COMPARATOR
Intervention: Bacterial vaginosis
Number of subjects: 151
Study 17879534 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80
Study 17879534 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 15735119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone (35 mg/m²) alone
Number of subjects: 92
Study 15735119 — intervention group
Group type: COMPARATOR
Intervention: Ixabepilone + Estramustine Phosphate (EMP) (280 mg orally three times daily on days 1 to 5)
Number of subjects: 92
Study 11068226 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Hz magnetic fields at an occupational intensity (28.3 microTesla)
Number of subjects: 46
Study 11068226 — intervention group
Group type: COMPARATOR
Intervention: Control condition (< or =0.2 microT)
Number of subjects: 46
Study 9364263 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine and silver-sulfadiazine impregnated catheters (CH-SS)
Number of subjects: 680
Study 9364263 — intervention group
Group type: COMPARATOR
Intervention: Non-impregnated catheters
Number of subjects: 680
Study 1552366 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncooked extreme vegan diet for 1 month
Number of subjects: 18
Study 1552366 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional diet after vegan diet for 1 month
Number of subjects: 18
Study 1552366 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet throughout the study
Number of subjects: 18
Study 3907071 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric aspiration with a wide-bored tube
Number of subjects: 40
Study 3907071 — intervention group
Group type: COMPARATOR
Intervention: Fasting for six hours without gastric aspiration
Number of subjects: 40
Study 31074815 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic screening and personalized feedback with clinician clinical decision support
Number of subjects: 300
Study 31074815 — intervention group
Group type: COMPARATOR
Intervention: Standard screening and counseling as provided by their clinic (Control)
Number of subjects: 300
Study 29064556 — intervention group
Group type: EXPERIMENTAL
Intervention: BITE supervision (live computer‐based supervision during a psychotherapy session)
Number of subjects: 42
Study 29064556 — intervention group
Group type: COMPARATOR
Intervention: Delayed video‐based (DVB) supervision
Number of subjects: 42
Study 26824902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopimune (Lopinavir/Ritonavir), 1 capsule twice daily for 2 weeks, self-applied as a vaginal pessary
Number of subjects: 23
Study 24331777 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise and nutritional guidance for 6 months
Number of subjects: 114
Study 24331777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 114
Study 20641031 — intervention group
Group type: COMPARATOR
Intervention: Calcium 1 g/day
Number of subjects: 1794
Study 20641031 — intervention group
Group type: COMPARATOR
Intervention: Calcium 600 or 1200 mg/day
Number of subjects: 1794
Study 20641031 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation
Number of subjects: 1794
Study 20641031 — intervention group
Group type: COMPARATOR
Intervention: Calcium intake
Number of subjects: 1794
Study 20641031 — intervention group
Group type: COMPARATOR
Intervention: Low bone mineral density (BMD)
Number of subjects: 1794
Study 19100933 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.06 mg/kg)
Number of subjects: 110
Study 19100933 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 110
Study 16860974 — intervention group
Group type: EXPERIMENTAL
Intervention: Definition 1 (PANSS items sustained over at least 6 months)
Number of subjects: 0